Blue Apron More Than Doubles In Pre-market After Merger Deal With Wonder Group

Shares of Blue Apron Holdings, Inc. (APRN) are trading up over 133 percent on Friday morning, after the company announced a merger deal to be acquired by Wonder Group.

from RTT - Before the Bell https://ift.tt/0RXVdim
via IFTTT

Read More »

Baudax Bio: FDA Grants Orphan Drug Designation To TI-168 For Hemophilia A With Inhibitors

Baudax Bio, Inc. (BXRX), a biotechnology company, announced Thursday that the U.S. Food and Drug Administration or FDA has granted orphan drug designation to its lead clinical candidate TI-168 for the treatment of Hemophilia A with inhibitors.

from RTT - Before the Bell https://ift.tt/ZvuQodl
via IFTTT

Read More »

CarMax Slips Over 13% In Pre-market After Q2 Profit, Revenue Decline

Shares of CarMax, Inc. (KMX) were trading down on Thursday after the company reported a fall in earnings for the second-quarter, below the analysts' estimates.

from RTT - Before the Bell https://ift.tt/CVX1osm
via IFTTT

Read More »

Accenture Issues FY24 Guidance

Accenture (ACN) said, for fiscal 2024, the company expects GAAP EPS to be in the range of $11.41 to $11.76, an increase of 6% to 9% over fiscal 2023. Adjusted EPS is projected to be in the range of $11.97 to $12.32, an increase of 3% to 6% over fiscal 2023. The company noted that the guidance excludes $0.56 for business optimization costs in fiscal 2024.

from RTT - Earnings https://ift.tt/ArQJslc
via IFTTT

Read More »

Paychex Updates FY24 Business Outlook

Paychex, Inc. (PAYX) said the company now expects fiscal 2014 adjusted earnings per share growth in a range of 9% to 11%. Previously, the company projected adjusted earnings per share growth in the range of 9% to 10%. Interest on funds held for clients is now anticipated to be in the range of $140 million to $150 million. The company noted that the other aspects of guidance for fiscal 2024 remain unchanged.

from RTT - Earnings https://ift.tt/UQPTV7t
via IFTTT

Read More »

Marriott Projects 15% To 20% Growth In Adj. EPS Over Three-Year Period

Marriott International, Inc. (MAR) presented the company's three-year financial model through 2025. As per the assumptions in its three-year model, adjusted earnings per share could rise 25 to 29 percent year-over-year in 2023 and at a 10 to 15 percent two-year CAGR to reach $10.10 to $11.45 in 2025. Adjusted EBITDA could rise 18 to 21 percent year-over-year in 2023 and at a 7 to 10 percent two-year CAGR to reach $5.2 to $5.7 billion in 2025. Total gross fee revenues are projected to rise 16 to 18 percent year-over-year in 2023 and at a 6.5 to 9.5 percent two-year CAGR to reach $5.4 to $5.8 billion in 2025. Marriott shareholders could see $1.9 to $2.0 billion in dividends, assuming a 25 percent payout ratio, and $9.8 to $11.6 billion in share repurchases, for total shareholder returns of $11.7 to $13.6 billion over the three-year period.

from RTT - Earnings https://ift.tt/rdhxCnU
via IFTTT

Read More »

General Mills Reaffirms FY24 Outlook - Update

While reporting financial results for the first quarter on Wednesday, branded food company General Mills, Inc. (GIS) reaffirmed its adjusted earnings growth and organic net sales growth outlook for the full-year 2024.

from RTT - Earnings https://ift.tt/oidgrwG
via IFTTT

Read More »

Liberty Media Proposes To Combine With Sirius XM Holdings; Stocks Move In Premarket

Liberty Media Corp. (LSXMK) announced on Tuesday that it has communicated a proposal to Sirius XM Holdings Inc. (SIRI), an audio entertainment company, to combine Liberty SiriusXM tracking stock group or LSXM with SiriusXM. This would create a new consolidated public company, New SiriusXM.

from RTT - Before the Bell https://ift.tt/aUIRPKb
via IFTTT

Read More »

United Natural Foods Posts Loss In Q4; Announces Board-led Financial Review, Shares Plummet

United Natural Foods, Inc. (UNFI) posted a fourth-quarter net loss of $68 million compared to net income of $39 million, prior year. Net loss per share was $1.15 compared to net income per share of $0.63. Adjusted loss per share was $0.25, compared to adjusted profit of $1.27. On average, 11 analysts polled by Thomson Reuters expected the company to report a loss per share of $0.28, for the quarter. Analysts' estimates typically exclude special items. Adjusted EBITDA decreased 56.3% to $93 million.

from RTT - Earnings https://ift.tt/43pOu5N
via IFTTT

Read More »

Scynexis Recalls GSK- Licensed Ibrexafungerp Tablets, Halts Trials On Contamination Concerns

Scynexis Inc. (SCYX), which is in exclusive license deal with GSK plc (GSK, GSK.L) for antifungal drug Brexafemme (ibrexafungerp tablets), said it is recalling the drug from the market and placing a temporary hold on clinical studies of ibrexafungerp, citing cross contamination concerns.

from RTT - Before the Bell https://ift.tt/CMjP8sK
via IFTTT

Read More »

Cara Therapeutics To Get $1.5 Mln Payment As KORSUVA IV Injection Syringe Approved In Japan

Cara Therapeutics, Inc. (CARA), a commercial-stage biopharmaceutical company focused on pruritus, announced Monday the Approval of KORSUVA IV Injection Syringe in Japan to treat pruritus in hemodialysis patients. The company now would receive $1.5 million milestone payment from its licensing partner Maruishi Pharmaceutical Co., Ltd under the deal.

from RTT - Before the Bell https://ift.tt/UM0i5Iw
via IFTTT

Read More »

Seagen Up In Pre-Market After Positive Results From EV-302 Trial

Shares of Seagen Inc. (SGEN) are trading up over three percent on Friday after the company released positive results from EV-302 trial.

from RTT - Before the Bell https://ift.tt/HbfaXz6
via IFTTT

Read More »

Cisco To Buy Cybersecurity Firm Splunk In $28 Bln Deal; Stock Down In Premarket

Cisco Systems Inc. (CSCO) announced Wednesday its agreement to acquire Splunk Inc. (SPLK), a c and observability company, for $157 per share in cash, representing around $28 billion in equity value.

from RTT - Before the Bell https://ift.tt/a2FHbKB
via IFTTT

Read More »

FactSet Q4 Profit Misses Estimates; Organic Revenue Up 7.2%

FactSet (FDS) reported that its fourth quarter net income declined to $65.1 million from $104.4 million, prior year. GAAP earnings per share decreased 37.5% to $1.68, mainly due to non-recurring charges and the higher tax provision, which had a $0.68 impact. Adjusted net income was $113.6 million, down 6.5%. Adjusted EPS decreased 6.4% to $2.93, compared with $3.13, last year, mainly due to non-recurring charges and the higher tax provision, which had a $0.68 impact. On average, 15 analysts polled by Thomson Reuters expected the company to report profit per share of $3.50, for the quarter. Analysts' estimates typically exclude special items.

from RTT - Earnings https://ift.tt/m1rgV7z
via IFTTT

Read More »

General Mills Reaffirms FY24 Outlook - Update

While reporting financial results for the first quarter on Wednesday, branded food company General Mills, Inc. (GIS) reaffirmed its adjusted earnings growth and organic net sales growth outlook for the full-year 2024.

from RTT - Earnings https://ift.tt/FenDw1N
via IFTTT

Read More »

Kingfisher H1 Adj. Pretax Profit Declines, LFL Sales Down 2.2%; Updates FY Profit Outlook

Kingfisher PLC (KGF.L) reported that its first half pretax-profit declined to 317 million pounds from 474 million pounds, last year, reflecting lower operating profit, including the impact of impairments reflecting revised future projections. Earnings per share was 12.2 pence compared to 18.3 pence. Adjusted pretax profit declined to 336 million pounds from 472 million pounds, last year, reflecting lower retail profit and higher central costs and share of JV interest and tax, partially offset by lower net finance costs. Adjusted earnings per share was 12.8 pence compared to 18.0 pence.

from RTT - Earnings https://ift.tt/HX3C0AB
via IFTTT

Read More »

Delta Air Lines Updates Q3 Guidance; Reaffirms FY Earnings Outlook

Delta Air Lines Inc. (DAL, DALRQ.PK) announced the company now expects September quarter non-GAAP earnings per share in a range of $1.85-$2.05, revised from prior guidance of $2.20-$2.50. Non-GAAP operating margin is anticipated to be approximately 13%, updated from prior guidance of mid-teens.

from RTT - Earnings https://ift.tt/W2RzbYa
via IFTTT

Read More »

Koppers Expects To Exceed Prior Full-year Guidance; Affirms Sales Forecast

Koppers Holdings Inc. (KOP) affirmed previous forecast for 2023 sales of approximately $2.1 billion, while increasing both adjusted EBITDA and adjusted earnings per share guidance. Adjusted EBITDA is now anticipated to be in the range of $250 million to $260 million, compared with $250 million previously. Adjusted EPS is now expected to be in the range of $4.30 to $4.60 per share, compared with $4.40 previously.

from RTT - Earnings https://ift.tt/COgEW4u
via IFTTT

Read More »

American Airlines Cuts Q3 Adj. EPS View Below Market; Lifts Capacity View; Stock Down In Premarket

American Airlines Group, Inc. (AAL) on Wednesday trimmed its third-quarter earnings outlook, citing certain expenses and significantly higher fuel prices since the initial guidance issued on July 20.

from RTT - Before the Bell https://ift.tt/XHsOBpT
via IFTTT

Read More »

Eiger To Discontinue Peginterferon Lambda Trial In CHD Patients; Stock Down In Premarket

Eiger BioPharmaceuticals, Inc. (EIGR), a commercial-stage biopharmaceutical company focused on rare metabolic diseases, Wednesday said it has decided to discontinue the Phase 3 LIMT-2 study of peginterferon lambda in patients with chronic hepatitis delta or CHD.

from RTT - Before the Bell https://ift.tt/G8M3Spk
via IFTTT

Read More »

REV Group Q3 Results Top Estimates; Boosts FY23 Outlook

REV Group, Inc. (REVG), a manufacturer of specialty vehicles, on Wednesday reported that net income for the third quarter plunged to $14.9 million or $0.25 per share from $9.5 million or $0.16 per share in the prior-year quarter.

from RTT - Earnings https://ift.tt/H4vJ13l
via IFTTT

Read More »

Spirit Airlines Cuts Q3 Revenue View Below Market; Stock Down In Premarket

Spirit Airlines, Inc. (SAVE), an ultra-low cost airline, on Wednesday trimmed its adjusted margin and revenue forecast for its third quarter.

from RTT - Before the Bell https://ift.tt/pbZiE0L
via IFTTT

Read More »

Cognyte Q2 Loss Narrows, Updates FY24 Outlook; Stock Up In Pre Market

Cognyte Software Ltd. (CGNT) on Tuesday reported narrower loss for its second quarter, amid weak revenues. The company also updated its outlook for fiscal 2024.

from RTT - Before the Bell https://ift.tt/26dEugX
via IFTTT

Read More »

Humacyte Reports Positive Top Line Trial Results Of Human Acellular Vessel To Treat Vascular Trauma

Humacyte, Inc. (HUMA), a clinical-stage biotechnology company focused on universally implantable, bioengineered human tissue at commercial scale, announced Tuesday positive top line results from its V005 Phase 2/3 trial of the Human Acellular Vessel or HAV in vascular trauma repair.

from RTT - Before the Bell https://ift.tt/TFkPUMp
via IFTTT

Read More »

Sight Sciences Issues Q3 View, Cuts FY23 Revenue Outlook Below Market; Stock Down In Premarket

Sight Sciences, Inc. (SGHT), an eyecare technology company, on Tuesday issued a third-quarter revenue guidance, and trimmed its revenue outlook for fiscal 2023, below market estimates.

from RTT - Before the Bell https://ift.tt/H9j24Xq
via IFTTT

Read More »

Associated British Foods Sees FY Adj. Operating Profit Slightly Better Than Prior Outlook

Associated British Foods PLC (ASBFY.PK, ABF.L) issued an update prior to entering the close period for its full year results for the 52 weeks to 16 September 2023. The Group said, overall, outlook for the financial year is slightly better than previous expectations of Group adjusted operating profit to be moderately ahead of last year.

from RTT - Earnings https://ift.tt/Az6DCJ3
via IFTTT

Read More »

NovaBay Pharma Agrees With BioStem To Commercialize Amniotic Tissue Allograft As Avenova Allograft

NovaBay Pharmaceuticals, Inc. (NBY) announced Monday an agreement to commercialize BioStem Technologies, Inc.'s (BSEM) Amniotic Tissue Allograft as Avenova Allograft. The company plans to launch Avenova Allograft in the coming weeks.

from RTT - Before the Bell https://ift.tt/iv6eQql
via IFTTT

Read More »

BioLineRx: FDA Approves APHEXDA Plus Filgrastim To Mobilize Hematopoietic Stem Cells; Stock Up

BioLineRx Ltd. (BLRX), a commercial stage biopharmaceutical company focused on certain cancers and rare diseases, announced Monday that the U.S. Food and Drug Administration or FDA has approved APHEXDA (motixafortide) in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood. This is for collection and subsequent autologous transplantation in patients with multiple myeloma.

from RTT - Before the Bell https://ift.tt/FqW8g6Z
via IFTTT

Read More »

Kroger Reaffirms FY23 Outlook - Update

While reporting financial results for the second quarter on Friday, supermarket chain Kroger Co. (KR) reaffirmed its adjusted earnings and identical sales outlook for the full-year 2023. Identical sales growth for the second quarter, without fuel, increased 1.0 percent, with underlying growth of 2.6 percent.

from RTT - Earnings https://ift.tt/V2xpv4r
via IFTTT

Read More »

HanesBrands In Licensing Deal With G-III Apparel For Champion And C9 Champion Outerwear

Basic apparel maker HanesBrands, Inc. (HBI) Thursday said it has entered into a strategic multi-year license agreement for Champion and C9 Champion Outerwear with G-III Apparel Group, Ltd. (GIII).

from RTT - Before the Bell https://ift.tt/LmErn53
via IFTTT

Read More »

Science Applications International Q2 Results Top Estimates; Boosts FY24 Outlook

Technology integrator Science Applications International Corp. (SAIC) announced Thursday that net income for the second quarter soared to $247 million or $4.56 per share from $74 million or $1.30 per share in the prior-year quarter.

from RTT - Earnings https://ift.tt/la2xPwe
via IFTTT

Read More »

Swiss Life Group H1 Profit Rises On Comparable Basis

Swiss Life Group (SZLMY.PK, SLHN.VX) reported first half net profit of 630 million Swiss francs. In the prior-year, net profit was 560 million francs, on a comparable basis. Under IFRS 17 and the now discontinued IAS 39 standard, prior-year net profit would have been 710 million francs.

from RTT - Earnings https://ift.tt/3GEqieb
via IFTTT

Read More »

Salzgitter Shares Down After Suspending FY23 Outlook As Aurubis Says Won't Reach Target

Shares of Salzgitter AG (SZGPY.PK) were losing around 6 percent in the morning trading in Germany after the steel manufacturer Friday said that it is suspending earnings guidance for fiscal 2023 for the time being. The move follows the outlook revision by non-ferrous metal supplier Aurubis AG (AIAGY.PK), in which Salzgitter holds 29.99 percent stake.

from RTT - Before the Bell https://ift.tt/RYHVbN1
via IFTTT

Read More »